elective PTCA and 6 hours and 24 hours after PTCA and to compare the assay differences with CK-MB, myoglobin, and cardiac troponin I (cTn-I) differences.
Methods
In this prospective study, 42 patients without evidence for acute myocardial infarction scheduled for elective PTCA and 13 control patients scheduled for elective diagnostic coronary angiography were enrolled at two hospitals: Swedish Medical Center, Englewood, Colo, and Centura Health Porter Adventist Hospital, Denver, Colo. Institutional review boards of both hospitals approved the study protocol, and all patients gave informed consent. Patients were excluded if they had any of the following: signs or symptoms of other acute or chronic ischemic conditions (including but not limited to stroke, transient ischemic attack, claudication, diabetes mellitus with signs of peripheral vascular disease, kidney failure, or shock), evidence of collateral coronary circulation around the target angioplasty lesion, 18, 19 use of a continuous-perfusion balloon catheter or intra-aortic balloon pump during PTCA, >72 hours of known occlusion of the coronary artery targeted for angioplasty, cardiac arrest or another coronary revascularization procedure during or in the 24 hours after PTCA, or previous enrollment in this study. A clinical cardiologist blinded to all ACB assay results retrospectively reviewed each patient's complete medical record to exclude any patient who demonstrated objective evidence of acute myocardial infarction <72 hours before PTCA (unequivocal electrocardiographic abnormalities, serial CK-MB or troponin elevations, or angiographic evidence of acute myocardial infarction), angiographic evidence of >72 hours of known occlusion of the coronary artery lesion targeted for PTCA, or significant collateral coronary circulation at the angioplasty site documented during PTCA. One patient was excluded because of lost baseline blood samples, leaving a final study group of 41 patients with PTCA. A control group for preprocedure and postprocedure ACB assay values included 13 patients who received diagnostic coronary angiography without PTCA.
Interventional cardiologists blinded to all study assay results performed PTCA and diagnostic coronary angiography according to standard hospital protocols. All patients received standardized medical care before and after the procedure. Decisions regarding the number of balloon inflations, whether or not to use intraluminal stents, and when to terminate the procedure were based entirely on the clinical judgment of the interventional cardiologists.
All patients had baseline blood samples collected from the distal aorta catheter port into tubes with sodium heparin before receiving any contrast material. Blood samples were drawn in a similar fashion immediately after the last balloon inflation in the PTCA group and at the end of diagnostic coronary angiography in the control group. For follow-up samples, patients in the study group had additional venous blood samples collected in heparinized tubes 6 hours and 24 hours after PTCA. Plasma aliquots were prepared for CK-MB, myoglobin, and cTn-I analysis, and additional aliquots were stored at 4°C for ACB assay batched analysis <48 hours after the last sample collection.
ACB assay
Colorimetric ACB assays were performed with the use of a Beckman DU-62 model spectrophotometer (470 nm) at the Trauma Research Laboratory, Swedish Medical Center, by one technician blinded to sample time and collection order. Triplicate values were averaged for all ACB assay calculations for each patient sample. The ACB assay laboratory method has been described in detail in a previous report. 9 No ACB assay normal values have yet been established for patients with known preexisting coronary disease. Thus ACB assay values for patients with PTCA and control patients were recorded as a percent change from baseline to lessen any effect of silent ischemia or ischemic preconditioning on baseline values. 20, 21 A mean of all replicate assay measurements was determined before calculation of percent change.
Cardiac markers
All CK-MB, myoglobin, and cTn-I assays were performed in a blinded fashion at the clinical laboratory at Swedish Medical Center. CK-MB mass, myoglobin, and cTn-I were all determined by means of a 2-site sandwich monoclonal antibody immunoassay with the Dade Behring Stratus CS STAT Fluorometric Analyzer (Dade Behring Inc, Newark, Del). Upper reference limits for the CK-MB, myoglobin, and cTn-I assays were 4.5 ng/mL, 110 ng/mL, and 1.4 ng/mL, respectively. As with the ACB assay, CK-MB, myoglobin, and cTn-I values were reported as a percent change from baseline.
Statistical analysis
Study group and control group data are expressed as mean value ± SD and as median and 25th and 75th percentiles. Percent change was calculated as follows: (Assay level after PTCA or angiography alone -Baseline assay level before PTCA or angiography alone) × 100/Baseline assay level before PTCA or angiography alone. Data analysis was performed with Microsoft Excel 2000 (Redmond, Wash). Intraoperator variability for the ACB assay was reported as percent coefficient of variation. A Student t test was used to analyze the difference between means. The mean difference between preprocedure and postprocedure was compared by means of a 2-tailed, 2-sample t test. A value of P ≤ .05 was considered significant.
Results

Study group patient characteristics
Study group clinical characteristics are represented in Table I . The PTCA study group of 41 patients included 26 (63%) men and 15 (37%) women; the mean age was 62.8 years (range, 41 to 83), with 30 (73%) of 41 having ≥2 risk factors for coronary artery disease, 10 (24%) of 41 having unstable angina, and 20 (49%) of 41 having had a prior revascularization procedure (Table II) . A high percentage of study group patients (33 [81%] of 41) had at least one of the following signs of myocardial ischemia during the procedure: significant chest pain, ST-segment changes >1 mm, or ventricular rhythm disturbances. Stents were used with angioplasty for 37 (90%) of 41 study group patients, and 5 (12%) of 41 study group patients had side branch occlusions (SBO). No PTCA study group patients received β-blockers before or during PTCA; 12 (29%) of 41 received calcium channel blockers; 7 (17%) of 41 received abciximab; 35 (85%) of 41 received aspirin; and 41 (100%) of 41 received intravenous heparin. Angiographic characteristics for the 41 PTCA study group patients are listed in Table II .
Control group patient characteristics
Control group clinical characteristics are represented in Table I . The control group of 13 patients undergoing diagnostic coronary angiography without PTCA included 9 (69%) men and 4 (31%) women; the mean age was 49.9 years (range, 33 to 63), with 10 (77%) of 13 having ≥2 risk factors for coronary artery disease. Four (31%) of the 13 control patients had angiographic coronary lesions that did not require angioplasty, and 2 of the patients with coronary lesions had multivessel disease. No control group patient had significant chest pain, ST-segment changes >1 mm, or ventricular rhythm disturbances during the angiographic procedure. None of the control group patients received abciximab with the procedure, but 11 (85%) of 13 received aspirin, and 11 (85%) of 13 received intravenous heparin (Table II) .
Albumin-cobalt assay results in the study group ACB assay intraoperator variability for the PTCA study group replicate values was considered acceptable, with a mean coefficient of variation of 3.4% (range, 0.2% to 13.7%).
Of the 41 patients in the PTCA group, 34 (83%) showed an increase in ACB assay values after PTCA compared with baseline. Mean ACB assay values were 0.350 ± 0.043 ABSU (absorbance units) at baseline and 0.383 ± 0.044 ABSU immediately after PTCA. Mean percent difference in ACB values after PTCA compared with baseline was 10.1% ± 11.1% (P < .000001) (95% confidence interval, 6.7% to 13.5%). The mean percent difference for the study group was significantly greater compared with the 13 patients in the control group (10.1% ± 11.1% vs -0.9% ± 8.2%, P < .001). Of the 41 PTCA patients enrolled in the study group, 2 patients (2 [5%] of 41) refused further blood collection at 6 hours, and 15 patients (15 [37%] of 41) either refused further blood collection or were discharged from the hospital and could not be located for the 24-hour blood sample. None of the study group or control group patients died or had adverse reactions during the 24 hours after the procedure. In the final PTCA study group, ACB assay values were recorded in 41 of 41 patients at baseline and immediately after PTCA, in 39 of 41 patients at baseline and 6 hours after PTCA, and in 26 of 41 patients at baseline and 24 hours after PTCA. Data from 25 PTCA study group patients with all sample data available for ACB assay and all cardiac markers demonstrated that the results were essentially the same as for the entire 41-patient cohort (data not shown). The 39 patients sampled at 6 hours after PTCA and 26 patients sampled at 24 hours after PTCA had ACB values essentially unchanged from baseline, with mean percent differences of 2.7% and -1.8 %, respectively (Table III) . Median and 25th and 75th percentile ACB assay values are shown in Table IV . Within the PTCA study group, 7 (17%) patients had no increase in ACB assay levels compared with baseline at any time sampled after PTCA. Cardiac marker results in the study group ACB and cardiac marker assay mean differences from baseline are listed in Table III , and median and 25th and 75th percentiles are listed in Table IV . CK-MB, myoglobin, and cTn-I mean percent differences from baseline were not significantly elevated immediately after PTCA for the 41 study group patients. CK-MB, myoglobin, and cTn-I mean percent differences from baseline were significantly elevated at 6 hours and at 24 hours after PTCA (Table III) , but none of the median cardiac marker assay values were elevated above upper limits of normal at any time point after PTCA (Table IV) . In this preliminary study, we found no significant correlation between patients with post-PTCA elevated ACB assay values and later elevation of cardiac markers.
Albumin-cobalt assay results in the control group
ACB assay intraoperator variability for all control patient replicate values was considered acceptable, with a mean coefficient of variation of 3.8% (range, 0.0% to 19.4%). The percent difference in ACB values for the control group was -0.9% ± 8.2% (95% confidence interval, -5.4% to 3.6%). The control group demonstrated no change in ACB assay values between baseline and samples drawn immediately after angiography.
Discussion
This preliminary study is the first to report significantly reduced exogenous cobalt binding to the Nterminus of human albumin after transient arterial occlusion and reperfusion with PTCA. These data suggest that alterations of ACB, compared with baseline, occur within minutes after PTCA-induced ischemic changes and can be detected by elevated values of a new colorimetric ACB assay. 9 Additionally, the results indicate that elevated ACB assay levels return to baseline within 6 hours after PTCA. Cardiac markers of necrosis such as CK-MB, myoglobin, and troponin have been reported to be unreliable as diagnostic tests for the presence of mild, reversible myocardial ischemia; when used to help identify acute myocardial infarction they are often not elevated above normal during the first 3 to 6 hours after the onset of symptoms. [1] [2] [3] [4] 7, 8 CK-MB, myoglobin, and cTn-I results in this study provide additional evidence that these cardiac markers do not appear to be significantly elevated immediately after elective PTCA.
Percent difference from baseline
Assay
After PTCA (n = 41) P value 6 h (n = 39) P value 24 h (n = 26) P value
Albumin-cobalt 10. 
Alterations of cobalt-binding capacity of human albumin
In vitro studies of human albumin have demonstrated that the transition metals cobalt, copper, and nickel bind tightly at the N-terminus binding site. 10 Conditions such as acidosis, 22 reduced oxygen tension, membrane energy-dependent sodium, and calcium pump disruptions, which occur during myocardial ischemia, have been shown to structurally alter the N-terminus of albumin and thereby reduce the transition metal-binding capacity of the protein. 11, 23 Reperfusion after transient ischemic events includes free radical and iron and copper exposure, which may cause even more alterations to albumin than ischemia itself. 12, [23] [24] [25] Albumin may act as a sacrificial antioxidant to reduce localized injury during reperfusion. 26 
ACB assay
The ACB assay reported here has been previously described as a measurement of reduced cobalt-binding capacity in albumin in patients with acute myocardial ischemia. 9 In the current assay format, a predetermined amount of exogenous cobalt is added to plasma samples and indirectly detects ACB by measuring the remaining unbound cobalt. Elevated ACB assay results in this format indicate reduced cobalt-binding capacity of albumin. Other reported assay methods for albumincobalt binding involve liquid chromatography, mass spectrometry, and nuclear magnetic resonance and are not well suited for routine clinical analysis. 10, 11, 22 The ACB assay used in this study is a simple biochemical procedure that can be adapted for hospital laboratories.
Albumin-cobalt assay kinetics after PTCA
The results of this study suggest that mean plasma levels of the ACB assay are significantly elevated a few minutes after transient PTCA-induced coronary artery occlusion and reperfusion. The data correlate chronologically with the previously reported time period most likely to encompass intravascular and endothelial ischemic conditions that could alter the N-terminus of albumin in the coronary circulation. 12, 24, 25 This suggests that a significant reduction of the transition metalbinding capacity of human albumin occurs within minutes after transient mild myocardial ischemia. Patients in the control group without angioplasty did not demonstrate a mean elevation in ACB assay levels, which suggests that the study group differences were caused by transient balloon inflations rather than by coronary catheterization and contrast angiography alone.
Mean ACB assay levels were not significantly different from baseline at 6 hours and 24 hours after PTCA. These results suggest that reduced ACB occurs in the first minutes after brief coronary occlusion and reperfusion and is best detected in blood samples drawn soon after the onset of a suspected ischemic event. The availability of an assay that quickly indicates the presence of myocardial ischemia could help fill a diagnostic need for those occasions when patients with suspected heart disease are examined soon after the onset of symptoms. Additionally, any blood assay that consistently detects a brief ischemic event soon after its occurrence and returns to baseline within several hours may be clinically useful to identify repeated ischemic events occurring after the initial episode.
Comparison with cardiac markers
In this preliminary study, CK-MB, myoglobin, and cTn-I did not increase significantly immediately after PTCA when compared with baseline levels, but mean percent differences were significantly elevated at 6 and 24 hours after PTCA. However, in this study of patients with no evidence of a prior acute myocardial infarction, median values of these traditional cardiac markers were not elevated above established upper limits of normal at any time in the first 24 hours after elective PTCA. These results are similar to previous reports showing that CK-MB, myoglobin, and troponin I are not routinely elevated in the 2 to 6 hours after ischemic injury and that only a relatively small percentage of patients have abnormal elevations of these cardiac markers after PTCA. 14, 17 No correlation between the ACB assay and cardiac markers was demonstrated in this study.
Study limitations
This preliminary study has several limitations. We acknowledge that the PTCA cohort was small and that the control group was younger and had less extensive coronary artery disease than did the PTCA group. Also, missing several blood samples at 6 hours and 24 hours reduced the sample size for those time points. Blood samples drawn before and after angioplasty were drawn from arterial sites, whereas later samples were venous, and it is possible that comparing arterial and venous samples could have introduced a degree of error. The study design included only 3 sample collection time points after PTCA for comparison to baseline values. Having no blood samples drawn between the end of PTCA and 6 hours later may have missed the time of maximum ACB assay, myoglobin, and CK-MB elevation and may have missed a more precise time when ACB assay values return to baseline. Additionally, this preliminary study was not designed to distinguish transient myocardial ischemia from small areas of myocardial necrosis; it lacked a clearly defined "gold standard" for the diagnosis of transient myocardial ischemia and did not have clearly established normal values for the ACB assay. Chest pain, rhythm disturbances, ST changes, and ventricular wall motion abnormalities have been previously recorded with balloon inflation during angioplasty, but no symptom or electrocardiographic abnormality appears to occur with enough consistency to be a valid standard. 13, 15, 16, 27 Other variables such as preconditioning during PTCA, 20, 21, 28 undocumented small collateral coronary arteries at the site of angioplasty, 18, 19 and the use of intraluminal stents, heparin, abciximab, or other medications may have either prevented PTCA from being an optimal model of myocardial ischemia or interfered with ACB during this study. That may help to explain why some patients did not have elevated ACB assay values after PTCA. It is beyond the scope of this preliminary study to fully explore potential false-positive or false-negative ACB assay values, but several factors, such as severe hypoalbuminemia, the presence of metal chelators, and the sample collection time in relation to the onset of ischemia, could affect ABC assay results. In its current format, the ACB assay method does not directly measure ischemia-altered albumin but rather measures free unbound cobalt. Future formats may be developed that can directly measure human albumin that has been altered during ischemia.
Clinical implications and conclusions
Early myocardial ischemia without definitive electrocardiographic abnormalities is difficult to diagnose soon after the onset of clinical symptoms, particularly because of the absence of reliable diagnostic blood tests. 1, 4, 7, 8, 27 Current treatment protocols for the presence of suspected early myocardial ischemia often require prolonged hospital observation, serial cardiac marker results to rule out myocardial infarction, and stress tests and cardiac imaging tests. 1, [4] [5] [6] [7] This preliminary study suggests that a blood assay of reduced ACB of the N-terminus of human albumin is significantly elevated almost immediately after transient arterial occlusion during PTCA, and these results are detected long before significant elevations of CK-MB, myoglobin, or cTn-I. Future investigations are warranted to establish whether the ACB assay is a clinically useful diagnostic test for very early myocardial ischemia.
